{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:40:17Z","timestamp":1790217617805,"version":"4.1.0"},"reference-count":33,"publisher":"American Chemical Society (ACS)","issue":"15","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303681"],"award-info":[{"award-number":["82303681"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404449"],"award-info":[{"award-number":["82404449"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2021-I2M-1-042"],"award-info":[{"award-number":["2021-I2M-1-042"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2022-I2M-2-003"],"award-info":[{"award-number":["2022-I2M-2-003"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","award":["Y2302"],"award-info":[{"award-number":["Y2302"]}],"id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Tianjin Binhai New Area Health Commission General support projects","doi-asserted-by":"publisher","award":["2023BWKY026"],"award-info":[{"award-number":["2023BWKY026"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Tianjin Science and Technology Commission Enterprise Science and Technology Commissioner Project","doi-asserted-by":"publisher","award":["24YDTPJC00350"],"award-info":[{"award-number":["24YDTPJC00350"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Tianjin Key Medical Discipline Construction Project","doi-asserted-by":"publisher","award":["TJYXZDXK-009A"],"award-info":[{"award-number":["TJYXZDXK-009A"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cyclin-dependent kinase 19 (CDK19) has been identified as a promising target due to its high expression in prostate cancer (PCa) cells. This study focuses on optimizing the structure of CDK19-targeted imaging tracers. The linker of the lead compound was optimized based on previous structure\u2013activity relationships and cyclization strategy. Incorporating the spirocyclic structure optimized the binding conformation and increased the binding effect of the ligands, which was also reflected in its increased IC50 value. Mice imaging showed clearer tumor lesions and acceptable tissue safety. In addition, 68Ga-IRM-8c identified three distinct lesions in two advanced CRPC patients, located in the pelvis, sacrum, and prostate. The SUVmax values of these lesions were 3.31, 2.93, and 2.73, respectively, with tumor-to-nontumor (T\/NT) ratios of 2.30, 2.59, and 2.42. In conclusion, 68Ga-IRM-8c not only effectively detected lesions in PCa patients, but also preliminarily demonstrated tissue safety, further highlighting the potential of CDK19 in PCa diagnosis.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c01389","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T12:19:09Z","timestamp":1752841149000},"page":"16539-16550","source":"Crossref","is-referenced-by-count":2,"title":["Optimized CDK19\nPET Tracers: Spirocyclic-Driven Design\nand Prostate Cancer Imaging"],"prefix":"10.1021","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5487-1701","authenticated-orcid":true,"given":"Jiang","family":"Yu","sequence":"first","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yang","sequence":"additional","affiliation":[{"name":"Tianjin\u2019s Clinical Research Center for China , , ,","place":["Tianjin, China, 300060"]},{"name":"National Clinical Research Center for Cancer , , ,","place":["Tianjin, China, 300308"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Xu","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panfeng","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Cancer , , ,","place":["Tianjin, China, 300308"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjing","family":"Liu","sequence":"additional","affiliation":[{"name":"Tianjin\u2019s Clinical Research Center for China , , ,","place":["Tianjin, China, 300060"]},{"name":"National Clinical Research Center for Cancer , , ,","place":["Tianjin, China, 300308"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Hou","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Fu","sequence":"additional","affiliation":[{"name":"Tianjin\u2019s Clinical Research Center for China , , ,","place":["Tianjin, China, 300060"]},{"name":"National Clinical Research Center for Cancer , , ,","place":["Tianjin, China, 300308"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Tianjin\u2019s Clinical Research Center for China , , ,","place":["Tianjin, China, 300060"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfeng","family":"Gou","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-6167","authenticated-orcid":true,"given":"Yiliang","family":"Li","sequence":"additional","affiliation":[{"name":"Chinese Academy of Medical Sciences & Peking Union Medical College , , ,","place":["Tianjin, China, 300192"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Dai","sequence":"additional","affiliation":[{"name":"Tianjin\u2019s Clinical Research Center for China , , ,","place":["Tianjin, China, 300060"]},{"name":"National Clinical Research Center for Cancer , , ,","place":["Tianjin, China, 300308"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"3","key":"2026073103072157100_cit1","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/s1470-2045(19)30821-6","article-title":"Radiotheranostics:\nA Roadmap for Future Development","volume":"21","author":"Herrmann","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"2026073103072157100_cit2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41591-022-01759-6","article-title":"Theranostics\nCould Be Big Business in Precision Oncology","volume":"28","author":"Arnold","year":"2022","journal-title":"Nat. Med."},{"issue":"8","key":"2026073103072157100_cit3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranostics\nin Oncology: Current Challenges and Emerging Opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"2026073103072157100_cit4","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical Applications of Fibroblast Activation Protein\nInhibitor Positron Emission Tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"npj Imaging"},{"issue":"1","key":"2026073103072157100_cit5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41391-021-00394-5","article-title":"Advances in PSMA-Targeted\nTherapy for Prostate Cancer","volume":"25","author":"Wang","year":"2022","journal-title":"Prostate Cancer\nProstatic Dis."},{"issue":"16","key":"2026073103072157100_cit6","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.3390\/molecules27165231","article-title":"Radiopharmaceutical\nTreatments for Cancer Therapy, Radionuclides Characteristics, Applications,\nand Challenges","volume":"27","author":"Salih","year":"2022","journal-title":"Molecules"},{"issue":"8","key":"2026073103072157100_cit7","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1007\/s00259-021-05615-6","article-title":"Current Status and Future Perspective\nof Radiopharmaceuticals in China","volume":"49","author":"Hu","year":"2022","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"19","key":"2026073103072157100_cit8","doi-asserted-by":"publisher","first-page":"12497","DOI":"10.1021\/acs.jmedchem.2c01403","article-title":"Diagnostic\nand Therapeutic Radiopharmaceuticals","volume":"65","author":"Lindsley","year":"2022","journal-title":"J. Med.\nChem."},{"key":"2026073103072157100_cit9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological Determinants of PSMA Expression, Regulation\nand Heterogeneity in Prostate Cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat. Rev.\nUrol."},{"issue":"7","key":"2026073103072157100_cit10","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1158\/1078-0432.CCR-16-0094","article-title":"Pan-Cancer Analysis\nof the Mediator Complex Transcriptome\nIdentifies CDK19 and CDK8 as Therapeutic Targets in Advanced Prostate\nCancer","volume":"23","author":"Bragelmann","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"2026073103072157100_cit11","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ijc.32551","article-title":"Increased\nMediator Complex Subunit\nCDK19 Expression Associates with Aggressive Prostate Cancer","volume":"146","author":"Becker","year":"2020","journal-title":"Int. J. Cancer"},{"key":"2026073103072157100_cit12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.humpath.2021.07.006","article-title":"CDK19 as a Diagnostic\nMarker for High-Grade Prostatic Intraepithelial Neoplasia","volume":"117","author":"Offermann","year":"2021","journal-title":"Hum. Pathol."},{"issue":"1","key":"2026073103072157100_cit13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-020-01293-4","article-title":"Long Non-Coding\nRNA NEAT1 Promotes Bone Metastasis of Prostate Cancer through N6-methyladenosine","volume":"19","author":"Wen","year":"2020","journal-title":"Mol. Cancer"},{"issue":"11","key":"2026073103072157100_cit14","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1007\/s00259-023-06277-2","article-title":"PET Imaging of New Target CDK19 in\nProstate Cancer","volume":"50","author":"Dai","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"8","key":"2026073103072157100_cit15","doi-asserted-by":"publisher","first-page":"6726","DOI":"10.1021\/acs.jmedchem.4c00281","article-title":"Novel CDK19-Targeted\nRadiotracers: A Potential Design Strategy to Improve the Pharmacokinetics\nand Tumor Uptake","volume":"67","author":"Dai","year":"2024","journal-title":"J. Med. Chem."},{"issue":"38","key":"2026073103072157100_cit16","doi-asserted-by":"publisher","first-page":"7730","DOI":"10.1039\/D3OB01169K","article-title":"Diastereoselective Synthesis and Structure-Affinity\nRelationships of Sigma(1) Receptor Ligands with Spirocyclic Scaffold","volume":"21","author":"Winge","year":"2023","journal-title":"Org. Biomol. Chem."},{"issue":"6","key":"2026073103072157100_cit17","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/17460441.2022.2055544","article-title":"Recent in Vivo Advances of Spirocyclic\nScaffolds for Drug Discovery","volume":"17","author":"Batista","year":"2022","journal-title":"Expert. Opin.\nDrug Discovery"},{"issue":"16","key":"2026073103072157100_cit18","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1016\/j.bmcl.2014.06.081","article-title":"The Use of Spirocyclic\nScaffolds\nin Drug Discovery","volume":"24","author":"Zheng","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"2026073103072157100_cit19","doi-asserted-by":"publisher","first-page":"115595","DOI":"10.1016\/j.ejmech.2023.115595","article-title":"Design,\nSynthesis, and Biological Evaluation of Novel Spirocyclic Compounds\nas Potential Anti-Glioblastoma Agents","volume":"258","author":"Zhu","year":"2023","journal-title":"Eur.\nJ. Med. Chem."},{"issue":"4","key":"2026073103072157100_cit20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/md17040232","article-title":"Marine\nSpirotetronates: Biosynthetic Edifices That\nInspire Drug Discovery","volume":"17","author":"Braddock","year":"2019","journal-title":"Mar. Drugs"},{"issue":"22","key":"2026073103072157100_cit21","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.3390\/molecules24224165","article-title":"Spirocyclic\nMotifs in Natural Products","volume":"24","author":"Chupakhin","year":"2019","journal-title":"Molecules"},{"key":"2026073103072157100_cit22","doi-asserted-by":"publisher","first-page":"113263","DOI":"10.1016\/j.ejmech.2021.113263","article-title":"Anticancer\nPotential of Spirocompounds\nin Medicinal Chemistry: A Pentennial Expedition","volume":"215","author":"Bora","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"35","key":"2026073103072157100_cit23","doi-asserted-by":"publisher","first-page":"10693","DOI":"10.1021\/acs.jafc.2c02301","article-title":"Spiro Derivatives\nin the Discovery of New Pesticides: A Research Review","volume":"70","author":"Yu","year":"2022","journal-title":"J. Agric. Food Chem."},{"issue":"9","key":"2026073103072157100_cit24","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1080\/17460441.2016.1195367","article-title":"The Utilization of Spirocyclic Scaffolds\nin Novel Drug\nDiscovery","volume":"11","author":"Zheng","year":"2016","journal-title":"Expert Opin. Drug Discovery"},{"issue":"8","key":"2026073103072157100_cit25","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s40265-014-0229-1","article-title":"Tofogliflozin: First\nGlobal Approval","volume":"74","author":"Poole","year":"2014","journal-title":"Drugs"},{"issue":"11","key":"2026073103072157100_cit26","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1358\/dot.2014.50.11.2232267","article-title":"Tofogliflozin:\nA Highly Selective Sglt2 Inhibitor for the Treatment of Type 2 Diabetes","volume":"50","author":"Rosenwasser","year":"2014","journal-title":"Drugs Today"},{"issue":"16","key":"2026073103072157100_cit27","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s40265-015-0485-8","article-title":"Rolapitant:\nFirst Global Approval","volume":"75","author":"Syed","year":"2015","journal-title":"Drugs"},{"issue":"1","key":"2026073103072157100_cit28","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1021\/acs.jmedchem.0c01473","article-title":"Spirocyclic Scaffolds\nin Medicinal Chemistry","volume":"64","author":"Hiesinger","year":"2021","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026073103072157100_cit29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bju.14828","article-title":"Risk of Metastatic Disease on (68)\nGallium-Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed\nTomography Scan for Primary Staging of 1253 Men at the Diagnosis of\nProstate Cancer","volume":"124","author":"Yaxley","year":"2019","journal-title":"BJU Int."},{"issue":"1","key":"2026073103072157100_cit30","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00259-024-06856-x","article-title":"Immunohistochemical\nErg Positivity Is Associated with Decreased PSMA Expression and Lower\nVisibility in Corresponding [68Ga]Ga-PSMA-11 PET Scans of Primary\nProstate Cancer","volume":"52","author":"Rupp","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"21","key":"2026073103072157100_cit31","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.3390\/jcm10214909","article-title":"Potential\nTargets Other Than PSMA for Prostate Cancer Theranostics: A Systematic\nReview","volume":"10","author":"Gauthe","year":"2021","journal-title":"J. Clin. Med."},{"issue":"26","key":"2026073103072157100_cit32","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1200\/JCO.22.00208","article-title":"Evolving Role of Prostate-Specific Membrane Antigen-Positron\nEmission Tomography in Metastatic Hormone-Sensitive Prostate Cancer:\nMore Questions Than Answers?","volume":"40","author":"Hussain","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"2026073103072157100_cit33","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3390\/diagnostics12061387","article-title":"Multitarget Molecular Imaging in Metastatic Castration\nResistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine\nDifferentiation","volume":"12","author":"Vargas Ahumada","year":"2022","journal-title":"Diagnostics"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c01389","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/16539\/66298917\/acs.jmedchem.5c01389.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/15\/16539\/66298917\/acs.jmedchem.5c01389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:07:28Z","timestamp":1785481648000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/15\/16539\/5234996\/Optimized-CDK19-PET-Tracers-Spirocyclic-Driven"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":33,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,7,18]]},"published-print":{"date-parts":[[2025,8,14]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c01389","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]}}}